Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125404562 | 12540456 | 2 | F | 20160706 | 20160708 | 20160729 | PER | US-PFIZER INC-2016334200 | PFIZER | 61.00 | YR | M | Y | 142.40000 | KG | 20160729 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125404562 | 12540456 | 1 | PS | ATORVASTATIN CALCIUM. | ATORVASTATIN CALCIUM | 1 | Oral | 80 MG, 1X/DAY | 20702 | 80 | MG | FILM-COATED TABLET | QD | ||||||
| 125404562 | 12540456 | 2 | C | PRAZOSIN | PRAZOSIN | 1 | Oral | 1 DF, 1X/DAY (EACH MORNING) | 0 | 1 | DF | TABLET | QD | ||||||
| 125404562 | 12540456 | 3 | C | LISINOPRIL. | LISINOPRIL | 1 | Oral | 1 DF, 1X/DAY (EACH MORNING) | 0 | 1 | DF | TABLET | QD | ||||||
| 125404562 | 12540456 | 4 | C | INSULIN N | INSULIN HUMAN | 1 | Subcutaneous | 60 IU (44UNITS SUBCUTANEOUS INJ EACH MORNING, AND 16UNITS SUBCUTANEOUS INJ EACH BEDTIME) | 0 | 60 | IU | INJECTION | |||||||
| 125404562 | 12540456 | 5 | C | INSULIN RAPID | INSULIN NOS | 1 | Subcutaneous | 38 IU (22UNITS SUBCUTANEOUS INJ EACH MORNING, 16UNITS SUBCUTANEOUS INJ EACH BEDTIME) | 0 | 38 | IU | INJECTION | |||||||
| 125404562 | 12540456 | 6 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 1 DF, 2X/DAY | 0 | 1 | DF | TABLET | BID | ||||||
| 125404562 | 12540456 | 7 | C | GLYBURIDE. | GLYBURIDE | 1 | Oral | 1 DF, 2X/DAY | 0 | 1 | DF | TABLET | BID | ||||||
| 125404562 | 12540456 | 8 | C | FLONASE | FLUTICASONE PROPIONATE | 1 | Nasal | UNK, AS NEEDED (TWO SPRAYS EACH NOSTRIL ONCE A DAY OR WHEN NEEDED) | 0 | NASAL SPRAY | |||||||||
| 125404562 | 12540456 | 9 | C | ATENOLOL. | ATENOLOL | 1 | Oral | 10 MG, DAILY | 0 | 10 | MG | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125404562 | 12540456 | 1 | Blood cholesterol increased |
| 125404562 | 12540456 | 2 | Hypertension |
| 125404562 | 12540456 | 3 | Blood pressure management |
| 125404562 | 12540456 | 4 | Diabetes mellitus |
| 125404562 | 12540456 | 5 | Diabetes mellitus |
| 125404562 | 12540456 | 6 | Diabetes mellitus |
| 125404562 | 12540456 | 7 | Diabetes mellitus |
| 125404562 | 12540456 | 8 | Hypersensitivity |
| 125404562 | 12540456 | 9 | Hypertension |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125404562 | 12540456 | Affective disorder | |
| 125404562 | 12540456 | Depressed mood | |
| 125404562 | 12540456 | Depression | |
| 125404562 | 12540456 | Drug dose omission | |
| 125404562 | 12540456 | Emotional distress | |
| 125404562 | 12540456 | Fatigue | |
| 125404562 | 12540456 | Feeling abnormal | |
| 125404562 | 12540456 | Malaise | |
| 125404562 | 12540456 | Mood swings | |
| 125404562 | 12540456 | Muscle spasms | |
| 125404562 | 12540456 | Myalgia | |
| 125404562 | 12540456 | Thinking abnormal |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125404562 | 12540456 | 2 | 1995 | 0 | ||
| 125404562 | 12540456 | 3 | 1995 | 0 | ||
| 125404562 | 12540456 | 4 | 2001 | 0 | ||
| 125404562 | 12540456 | 5 | 2001 | 0 | ||
| 125404562 | 12540456 | 6 | 2001 | 0 | ||
| 125404562 | 12540456 | 7 | 2001 | 0 | ||
| 125404562 | 12540456 | 8 | 1992 | 0 | ||
| 125404562 | 12540456 | 9 | 1992 | 0 |